Advertisement
UK markets closed

  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     

  • FTSE 250

    20,286.03
    -45.77 (-0.23%)
     

  • AIM

    764.38
    -0.09 (-0.01%)
     

  • GBP/EUR

    1.1796
    -0.0009 (-0.07%)
     

  • GBP/USD

    1.2646
    +0.0005 (+0.04%)
     

  • Bitcoin GBP

    47,956.23
    -10.37 (-0.02%)
     

  • CMC Crypto 200

    1,261.57
    -22.26 (-1.73%)
     

  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     

  • DOW

    39,118.86
    -45.20 (-0.12%)
     

  • CRUDE OIL

    81.46
    -0.28 (-0.34%)
     

  • GOLD FUTURES

    2,336.90
    +0.30 (+0.01%)
     

  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

  • HANG SENG

    17,718.61
    +2.14 (+0.01%)
     

  • DAX

    18,235.45
    +24.90 (+0.14%)
     

  • CAC 40

    7,479.40
    -51.32 (-0.68%)
     
Property :

8 UK holiday home businesses you could buy now

A holiday let could be a very sound investment, providing a decent income, capital growth and — somewhere to escape

Here's What Key Metrics Tell Us About Walgreens (WBA) Q3 Earnings

Zacks Equity Research
·2-min read

Walgreens Boots Alliance (WBA) reported $36.35 billion in revenue for the quarter ended May 2024, representing a year-over-year increase of 2.6%. EPS of $0.63 for the same period compares to $1.00 a year ago.

The reported revenue represents a surprise of +1.07% over the Zacks Consensus Estimate of $35.96 billion. With the consensus EPS estimate being $0.67, the EPS surprise was -5.97%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Walgreens performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- U.S. Retail Pharmacy: $28.50 billion compared to the $27.89 billion average estimate based on five analysts. The reported number represents a change of +2.3% year over year.

  • Revenues- U.S. Healthcare: $2.13 billion compared to the $2.12 billion average estimate based on five analysts. The reported number represents a change of +7.6% year over year.

  • Revenues- International: $5.73 billion versus $5.74 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +2.8% change.

  • Adjusted operating income (loss)- U.S. Retail Pharmacy: $501 million versus $620.19 million estimated by four analysts on average.

  • Adjusted operating income (loss)- Corporate and Other: -$42 million versus -$57.38 million estimated by four analysts on average.

  • Adjusted operating income (loss)- U.S. Healthcare: -$22 million versus -$48.35 million estimated by four analysts on average.

  • Adjusted operating income (loss)- International: $175 million versus the four-analyst average estimate of $190.99 million.

View all Key Company Metrics for Walgreens here>>>

Shares of Walgreens have returned +5.2% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research